Chardan Lifts Price Target on Intellia Therapeutics to $30 From $27, Keeps Buy Rating<blockquote>Chardan将Intellia Therapeutics目标价从27美元上调至30美元,维持买入评级</blockquote>
Intellia Therapeutics (NTLA) has an average rating of overweight and mean price target of $26.85, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f